Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 24.965 USD 1.15% Market Closed
Market Cap: 3.2B USD

EV/EBIT
Enterprise Value to EBIT

37.8
Current
-13.8
Median
7.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
37.8
=
Enterprise Value
3B USD
/
EBIT
80.4m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average EV/EBIT: 45.8
37.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
199.1
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
hidden
2-Years Forward
EV/EBIT
hidden
3-Years Forward
EV/EBIT
hidden